The Final Rule was mooted for implementation over a staged transition period, determined by a service’s risk level, by 2028.

The US has been at the centre of a shift in global trade dynamics these last few weeks, resulting from a rise in geopolitical ...

The US Food and Drug Administration (FDA) has awarded 510(k) clearance to Fujirebio’s Lumipulse G pTau 217/β-Amyloid 1-42 ...

The global in vitro diagnostics (IVD) market has exhibited significant growth, with its valuation rising from $67,111 million in 2019 to an estimated $91,093 million by 2027. This ...

Surmodics operates via two reportable segments — Medical Device and In Vitro Diagnostics (IVD). In the reported quarter, sales in the Medical Device segment were $20.7 million, down 16.6% from ...

Health Sector Reform Commission (HSRC) recommended that medical representatives (MR) of pharmaceutical companies will ...